Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center, Open-Label, Phase Ib/II Trial

NCT07802184 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07802184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07802184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center, Open-Label, Phase Ib/II Trial
Lead sponsor
West China Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 10, 2026
Completion date
May 1, 2029
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer, metastatic pancreatic cancer